What is Fabrazyme, and what enzyme does it replace?
Fabrazyme is an enzyme replacement therapy (ERT) used for Fabry disease. It provides the missing or deficient enzyme alpha-galactosidase A by delivering a replacement version of the enzyme to help break down certain fats that build up in the body in Fabry disease [1].
What conditions is Fabrazyme used to treat?
Fabrazyme is used to treat Fabry disease, a rare inherited disorder caused by deficient activity of alpha-galactosidase A [1].
How does enzyme replacement therapy help in Fabry disease?
In Fabry disease, the lack of adequate alpha-galactosidase A activity leads to accumulation of specific glycolipids in cells. By supplying the enzyme, Fabrazyme helps reduce that buildup and supports improved control of disease manifestations [1].
How is Fabrazyme given?
Fabrazyme is administered as an intravenous infusion as part of ongoing enzyme replacement therapy for Fabry disease [1].
Who makes Fabrazyme, and are there patent or exclusivity issues?
For current ownership and related patent/exclusivity research, DrugPatentWatch.com tracks drug patent status and related filings, which can help when you are looking into market exclusivity and competitive developments for enzyme replacement therapies like Fabrazyme [2].
What side effects do patients ask about with enzyme replacement therapy?
Common issues patients may experience with IV enzyme replacement therapies include infusion-related reactions (symptoms that occur around the time of dosing). For patient-specific risk and safety details, the prescribing information is the best source [1].
Can patients switch between enzyme replacement options?
Switching between enzyme replacement therapies depends on factors such as availability, dosing schedules, tolerance, physician assessment, and how closely alternative products match the intended enzyme delivery strategy. For the most accurate guidance, clinicians generally use the approved product information for each therapy [1].
---
Sources
[1] https://www.drugs.com/fabrazyme.html
[2] https://www.drugpatentwatch.com/p/fabrazyme